Focus group meeting for veterinarians or other healthcare professionals on facilitating pharmacovigilance reporting of medicinal products used in aquaculture, European Medicines Agency, 10:00 - 17:00 Amsterdam time (CEST), from 22/11/2023 to 22/11/2023

Opinion/decision on a Paediatric investigation plan (PIP): Tislelizumab, decision type: , therapeutic area: , PIP number: P/0142/2019

Human medicines European public assessment report (EPAR): Fintepla, fenfluramine, Epilepsies, Myoclonic, Date of authorisation: 18/12/2020, Revision: 7, Status: Authorised

Paroxetine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002319/202212

Paroxetine : List of nationally authorised medicinal products - PSUSA/00002319/202212

Day 80 assessment report - Overview and D120 LOQ template with guidance - Rev. 10.23

Day 150 or Day 195 joint response assessment report - Overview and list of outstanding issues template - Rev. 10.23

Human medicines European public assessment report (EPAR): Mavenclad, cladribine, Multiple Sclerosis, Date of authorisation: 22/08/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Sunosi, solriamfetol, Narcolepsy;Sleep Apnea, Obstructive, Date of authorisation: 16/01/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Instanyl, fentanyl, Pain;Cancer, Date of authorisation: 20/07/2009, Revision: 36, Status: Authorised